4-甲基-2-吗啉-4-嘧啶-5-羧酸 | 873450-22-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4-甲基-2-吗啉-4-嘧啶-5-羧酸
• 英文名称: 4-methyl-2-(morpholin-4-yl)pyrimidine-5-carboxylic acid
• 英文别名: 4-methyl-2-morpholinopyrimidine-5-carboxylic acid；4-methyl-2-morpholin-4-ylpyrimidine-5-carboxylic acid
• CAS: 873450-22-7
• 化学式: C₁₀H₁₃N₃O₃
• mdl: MFCD09439070
• 分子量: 223.232
• InChiKey: PGIPXUSYFVXCJQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  75.6
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-aminotricyclo[3.3. 1.1^3,7]decan-1-ol 、 4-甲基-2-吗啉-4-嘧啶-5-羧酸 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 N-[(2r,5s)-5-hydroxyadamantan-2-yl]-4-methyl-2-morpholin-4-ylpyrimidine-5-carboxamide
  参考文献：
  名称：

  Optimisation of pharmacokinetic properties in a neutral series of 11β-HSD1 inhibitors

  摘要：

  11 beta-HSD1 is increasingly seen as an attractive target for the treatment of type II diabetes and other elements of the metabolic syndrome. In this program of work we describe how a series of neutral 2-thioalkyl-pyridine 11 beta-HSD1 inhibitors were optimized in terms of their pharmacokinetic properties to give compounds with excellent bioavailability in both rat and dog through a core change to pyrimidine. A potential reactive metabolite issue with 4-thioalkyl-pyrimidines was circumvented by a switch from sulfur to carbon substitution. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.08.070
• 作为产物：
  描述：

  ethyl 2-[(dimethylamino)methylene]-3-oxobutanoate 在 sodium methylate 、 sodium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 反应 8.0h， 生成 4-甲基-2-吗啉-4-嘧啶-5-羧酸
  参考文献：
  名称：

  Optimisation of pharmacokinetic properties in a neutral series of 11β-HSD1 inhibitors

  摘要：

  11 beta-HSD1 is increasingly seen as an attractive target for the treatment of type II diabetes and other elements of the metabolic syndrome. In this program of work we describe how a series of neutral 2-thioalkyl-pyridine 11 beta-HSD1 inhibitors were optimized in terms of their pharmacokinetic properties to give compounds with excellent bioavailability in both rat and dog through a core change to pyrimidine. A potential reactive metabolite issue with 4-thioalkyl-pyrimidines was circumvented by a switch from sulfur to carbon substitution. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.08.070

文献信息

• SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281
  申请人：GILL Adrian Liam

  公开号：US20090264401A1

  公开（公告）日：2009-10-22

  A compound of formula (I): and pharmaceutically-acceptable salts thereof wherein the variable groups are defined within; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described.

  一种具有化学式（I）的化合物： 及其药用盐，其中变量基团在其中定义；还描述了它们在抑制11βHSD1中的应用，制备它们的方法以及包含它们的药物组合物。
• NEW COMPOUNDS
  申请人：Proximagen Limited

  公开号：US20150258101A1

  公开（公告）日：2015-09-17

  The present invention provides certain compounds according to formula (I) which are inhibitors of SSAO activity wherein V, W, X, Y, Z, R 1 and R 2 are as defined in the specification.

  本发明提供了一些按照式(I)的化合物，这些化合物是SSAO活性的抑制剂，其中V、W、X、Y、Z、R1和R2如规范中所定义。
• IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS
  申请人：PROXIMAGEN LIMITED

  公开号：US20160046622A1

  公开（公告）日：2016-02-18

  The compounds of formula (I) are inhibitors of semicarbazide-sensitive amine oxidase (SSAO) activity useful in the treatment of inflammation, an inflammatory disease, an immune or an autoimmune disorder, or inhibition of tumour growth.

  式(I)的化合物是半卡巴肼敏感胺氧化酶（SSAO）活性的抑制剂，可用于治疗炎症、炎症性疾病、免疫或自身免疫性疾病，或抑制肿瘤生长。
• Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors
  申请人：PROXIMAGEN, LLC

  公开号：US10428066B2

  公开（公告）日：2019-10-01

  The compounds of formula (I) are inhibitors of SSAO activity wherein V, W, X, Y, Z, R1 and R2 are as defined in the claims.

  式（I）化合物是 SSAO 活性抑制剂 其中 V、W、X、Y、Z、R1 和 R2 如权利要求中所定义。
• Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors
  申请人：PROXIMAGEN, LLC

  公开号：US10766897B2

  公开（公告）日：2020-09-08

  The compounds of formula (I) are inhibitors of SSAO activity wherein V, W, X, Y, Z, R1 and R2 are as defined in the claims.

  式（I）化合物是 SSAO 活性抑制剂 其中 V、W、X、Y、Z、R1 和 R2 如权利要求中所定义。